AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03941860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO
Study NCT06528574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional root canal treatment
Description: Root canals will be irrigated by only side perforated needle
Study NCT06528574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic
Description: Root canals will finally receive activation of the irrigant by the ultrasonic part of the IVAC system
Study NCT03941860 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study NCT03941860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06528574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apical negative pressure
Description: Root canals will finally receive activation of the irrigant by the negative pressure part of the IVAC system
Study NCT06528574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Ultrasonic and negative pressure
Description: Root canals will finally receive activation of the irrigant by the IVAC system which is a combination of ultrasonic and apical negative pressure procedures.
Study NCT03941860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05803278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online enhancement training
Description: Online enhancement training lasting 3 months, using the InTempo app system (Gea-Metaphonology-Athena-reading/Ermes-writing) three times a week for twenty minutes. The training will include: Metaphonological Enhancement; Reading Enhancement; Writing Enhancement.
Study NCT03941860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03941860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05080803 — intervention group
Intervention type: DRUG
Intervention: intravitreal administration of bevacizumab/ranibizumab/aflibercept/desamethazone
Description: intravitreal administration
Study NCT05364541 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MyoVista wavECG
Description: A standard 12-Lead, multi-channel resting interpretive trans-thoracic electrocardiograph providing both a Glasgow Interpretive Analysis and unique MyoVista wavECG Information for the detection of Left Ventricular Diastolic Dysfunction.
Study NCT04879875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IscAlert
Description: 3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed after end of surgery.
Study NCT04879875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IscAlert 72h
Description: 3 IscAlert sensors in the limb undergoing surgery and two control sensors in the opposite limb are inserted and CO2 is measured continously. IscAlert sensors are removed 72 hours after end of surgery
Study NCT05859204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OT-led Exercise Group
Description: Participants will complete pre-intervention self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin 10-minute educational session that describes the purpose of the exercise intervention and methods to remain safe during the intervention such as self-monitoring techniques. Following completion of the educational session, participants will complete a 30-minute exercise intervention under the guidance of the OT, which includes warm-up, high intensity interval training cardio, strength, kick boxing, cool-down, and yoga. Following completion of the exercise regimen, participants will participate in a 10-minute discussion and reflection with the OT and complete post-intervention self-report surveys. Participants in the intervention arm will also receive routine daily occupational therapy educational sessions received by the treatment as usual arm.
Study NCT05859204 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual - OT Groups
Description: Participants will complete pre-session self-report surveys about mood, anxiety, energy, self-esteem, and activity handed out by the research team. At this point, an occupational therapist (OT) will begin daily educational session about the topic of choice for that day. Treatment groups are largely discussion-based and include the following topics: coping skills, self-esteem, sleep management, leisure, time management, life skills, decision making, and goal setting. Following completion of the educational session, participants will complete post-intervention self-report surveys.
Study NCT06187753 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory Profile
Description: The Sensory Profile has 125 items that represent 14 functions of sensory processing and allows parents to report on their child's behavior.
Study NCT05687305 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: White Noise
Description: White noise is produced by digitally combining sounds of equal frequency in the laboratory. Then, all of the frequencies in this sound are calibrated to generate noise at each frequency. If the contribution of each region to the noise level is the same, the noise is referred to as white noise. Waterfalls, ocean waves, and wind blowing through trees all produce similar to white noise. Patients in the intervention group are observed by the investigator on the 0th and 1st postoperative days.Before going to sleep, a bluetooth headset will be used to listen to white noise for 30 minutes and vital signs will be measured before and after the procedure.
Study NCT06113523 — intervention group
Intervention type: BIOLOGICAL
Intervention: monogenic obesity
Description: The DNA samples will be sequenced for the 71 obesity genes especially for the study.
Study NCT04938778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF Participants will engage in 8 weeks of 14 hours per night fasting
Study NCT04902807 — intervention group
Intervention type: BIOLOGICAL
Intervention: Collection of samples
Description: Blood, Urine and Stool samples will be collected from the participants.
Study NCT05760079 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: 750mg of Jarrow formulas taken three times daily for 30 days
Study NCT06226454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-993
Description: Suspension for oral administration.
Study NCT06226454 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for oral administration.
Study NCT05111912 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxenda
Description: If a participant does not tolerate the recommended target dose of Saxenda group (e.g., 3.0 mg once daily), the participant may stay at the preceding highest tolerable dose (e.g., 2.4 mg once daily).
Study NCT05644626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-B167
Description: Intravenous administration
Study NCT05644626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Intravenous administration
Study NCT05131217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute bout of Continuous Moderate Intensity Exercise
Description: In this experimental intervention subjects will cycle continuously at moderate intensity (VO2 corresponding to lactate threshold) until a 200 kcal equivalent energy expenditure is reached.
Study NCT05131217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute bout of High Intensity Interval Training
Description: In this experimental invention subjects will alternate between 1 minute of high intensity cycling (watts corresponding to 85% VO2peak) and 1 minute of low intensity cycling (watts corresponding to 35-40% VO2peak) until a 200 kcal equivalent energy expenditure is reached.
Study NCT05131217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: In this intervention placebo, subjects will lay down on a flat, soft surface for 30 minutes in a dimly light room. They will not be allowed to use any electronic devices or read during this time to avoid potentially influencing continuous data recording.
Study NCT06298448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory experiments before and after mepolizumab treatment
Description: Patients that start with mepolizumab treatment on the basis of the clinical disease course will be measured prior and after start of mepolizumab to evaluate the effects this medication has on various immunological parameters and microbiome
Study NCT06111378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: fish oil
Description: fish oil
Study NCT06111378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: linseed oil
Description: linseed oil
Study NCT06111378 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: walnut oil
Description: walnut oil
Study NCT06393309 — intervention group
Intervention type: DRUG
Intervention: Levetiracetam
Description: Patients with idiopathic generalized epilepsy who were under treatment with levetiracetam
Study NCT06393309 — intervention group
Intervention type: DRUG
Intervention: Sodium valproate
Description: Patients with idiopathic generalized epilepsy who were under treatment with valproate
Study NCT06485310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleconsultation for psychological support
Description: Teleconsultation with a nurse for psychological support, after the diagnosis has been announced, before hospitalization for the first treatment (chemotherapy, surgery, radiotherapy) in addition to the standard practice
Study NCT05142267 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.
Study NCT05142267 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxycodone
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.
Study NCT05142267 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naloxone
Description: In randomized order (crossover) across 3 laboratory sessions, participants will undergo laboratory evoked thermal pain response testing with: 1) 0.13 mg/kg of oral oxycodone (in 1mg/ml syrup) plus 20ml i.v. saline placebo, 2) 8mg of i.v. naloxone (in 20ml saline vehicle) plus oral placebo syrup (quantity matching oxycodone syrup volume), or 3) 20ml i.v. saline placebo plus oral placebo syrup (quantity matching oxycodone syrup volume).~Thermal pain testing utilizes a Medoc TSAII NeuroSensory Analyzer. This equipment is used to assess heat pain threshold and tolerance using an ascending method of limits protocol.
Study NCT06185660 — intervention group
Intervention type: DRUG
Intervention: sodium zirconium cyclosilicate (SZC)
Description: sodium zirconium cyclosilicate (SZC), 5g or 10g of white to grey powder in a foil-lined packet. Starting dose of SZC is 10g, administered three times a day orally as a suspension in water. When normokalaemia has been achieved, starting dose of 5g once daily is recommended, with possible titration up to 10g once daily, or down to 5g once every other day, as needed, to maintain a normal potassium level. No more than 10g once daily should be used for maintenance therapy.
Study NCT05061251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 2402234
Description: Patients will receive 3 doses of 5mg each of BAY 2402234. Drug will be given Day 1 and Day 2 prior to standard-of-care craniotomy for tumor resection and 1 dose on the morning of surgery.
Study NCT05034705 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional suction system
Description: This is the conventional method of using the dental high volume suction to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
Study NCT05034705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental aerosol box with modified high volume evacuation system
Description: The dental aerosol box will be equipped with an exit for the high volume suction to be attached to contain the aerosol generated during dental procedure. The saliva ejector will also be used.
Study NCT05229289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)
Study NCT05229289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard medical therapy (SMT):~Lactulose (Titrated to 2-3 soft bowel movements per day) Oral LOLA can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Oral BCAAs can be used as an alternative or additional agent to treat patients non-responsive to conventional therapy Diet Daily energy intakes of 35-40 kcal/kg ideal body weight Daily protein intake 1.2-1.5 g/kg/day Small meals or liquid nutritional supplements evenly distributed throughout the day Oral BCAA supplementation in patient's intolerant of dietary protein (to allow recommended nitrogen intake to be achieved and maintained)
Study NCT05229289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota Transplant
Study NCT05698173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 48 ml whole blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
Study NCT05698173 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: blood for Peripheral blood mononuclear cell (PBMC) and serum isolation
Study NCT06449833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozein and Metformin
Description: The experimental group will be treated with 10mg Henagliflozein and Metformin.
Study NCT06449833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linagliptin and Metformin
Description: The control group will be treated with 5mg Linagliptin and Metformin.
Study NCT06164626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraction
Description: extraction: in all groups, extraction will be performed
Study NCT06164626 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: extraction: in all groups, extraction will be performed Treatment with low-intensity infrared 808 nm laser therapy will be applied in 2 stages: one in the immediate postoperative period and 10 days after surgery.
Study NCT06164626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plenum® OSShp and Plenum® Guide
Description: extraction: in all groups, extraction will be performed Immediately after tooth extraction, the biomaterials Plenum® OSShp and Plenum® Guide (Brazil) will be added to the dental socket, serving as a bone substitute and maintaining alveolar dimensions.
Study NCT04947800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program + EA Lung Mu-Shu+ St36
Description: Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lung Mu-Shu points and St36 points
Study NCT04947800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program + Lv7/Gb26
Description: Standard of care pulmonary rehabilitation program plus electro-acupuncture with mA electricity at varying frequencies to the Lv7/Gb26 points
Study NCT05440110 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active and active TBS
Description: The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
Study NCT05440110 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham and active TBS
Description: The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50- Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min. Sham stimulation applies the same iTBS protocol with the sham coil.
Study NCT06396026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018 tablets
Description: Oral TLL-018 tablets taken orally 1 pieces BlD for 52 weeks
Study NCT06396026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Description: Oral Placebo tablets taken orally 1 pieces BlD for 12 weeks and then Oral TLL-018 tablets taken orally 1 pieces BlD for 40 weeks.
Study NCT06575491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided supraclavicular approach
Description: Patients submitted to Supraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
Study NCT06575491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infraclavicular approach
Description: Patients submitted to Infraclavicular approach for ultrasound-guided Subclavian veinous catheterization.
Study NCT05601453 — intervention group
Intervention type: PROCEDURE
Intervention: Elective redo transcatheter aortic valve implantation (redo-TAVI)
Description: Elective redo-TAVI procedure with the intention to treat the patient with a SAPIEN family valve implantation (currently the only registered medical devices for redo-TAVI use)
Study NCT05484999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals
Description: 12 weeks of medically tailored meals
Study NCT05484999 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meals
Description: 12 weeks of medically tailored meals
Study NCT05484999 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals + Social Support
Description: 12 weeks of medically tailored meals and12 weeks of social media based support
Study NCT05484999 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Waitlist Control Group (no intervention for first 4 months and then receive MamaMeals between 16-20 weeks postpartum)
Study NCT05149625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6
Description: continuous glucose monitoring device
Study NCT05043974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry immersion
Description: Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
Study NCT05350657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: 2 week isocaloric, high protein and low carbohydrate ketogenic diet
Study NCT06577480 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06244953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIER-HF-PC
Description: The patient will be assigned to one of the three levels of care which is determined by the results given by Distress Thermometer (DT) and the Integrated Palliative Care Outcome Scale (IPOS).
Study NCT06244953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Patient continues on clinical care by his/her cardiologist. If the cardiologist picks up their symptoms or other concerns, he/or can be referred to a specialist palliative care physician by the cardiologist.